THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES NOR IS IT A PROSPECTUS ANNOUNCEMENT. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, OUTSIDE INDIA



TATVA CHINTAN PHARMA CHEM LIMI

pursuant to the conversion of our Company to a public limited company, the name of our Company was changed to 'Tatva Chintan Pharma Chem Limited' and a fresh certificate of incorporation dated February 26, 2021 was issued to our Company by the RoC For further details on the changes in the name and registered office of our Company, see "History and Certain Corporate Matters" on page 171 of the red herring prospectus of our Company dated July 10, 2021 ("RHP" or "Red Herring Prospectus") filed with the RoC and thereafter with the Securities and Exchange Board of India ("SEBI"), BSE Limited ("BSE") and National Stock Exchange of India Limited ("NSE" and together with BSE, the "Stock Exchanges").

Registered Office: Plot No. 502/17, GIDC Estate, Ankleshwar, Bharuch, Gujarat - 393 002, India; Telephone: +91 75730 46951/+91 75730 46952; Corporate Office: Plot No. 353, Makarpura GIDC, Vadodara, Gujarat - 390 010, India

Contact Person: Apurva Dubey, Company Secretary and Compliance Officer; Telephone: +9175748 48533/+9175748 48534; E-mail: cs@tatvachintan.com; Website: www.tatvachintan.com; Corporate Identity Number: U24232GJ1996PLC029894

OUR PROMOTERS: AJAYKUMAR MANSUKHLAL PATEL, CHINTAN NITINKUMAR SHAH AND SHEKHAR RASIKLAL SOMANI

INITIAL PUBLIC OFFERING OF UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹10 EACH ("EQUITY SHARES") OF TATVA CHINTAN PHARMA CHEM LIMITED ("OUR COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹ [●] PER EQUITY SHARE (INCLUDING A PREMIUM OF ₹ [●] PER EQUITY SHARE) ("OFFER PRICE") AGGREGATING UP TO ₹ 5,000.00 MILLION. THE OFFER COMPRISES OF A FRESH ISSUE OF UP TO [●] EQUITY SHARES AGGREGATING UP TO ▼ ₹ 2,250.00 MILLION ("FRESH ISSUE") AND AN OFFER FOR SALE OF UP TO [●] EQUITY SHARES AGGREGATING UP TO ₹ 2,750.00 MILLION, COMPRISING UP TO [●] EQUITY SHARES AGGREGATING UP TO ₹ 233.00 MILLION BY AJAYKUMAR MANSUKHLAL PATEL, UP TO [●] EQUITY SHARES AGGREGATING UP TO ₹ 814.00 MILLION BY CHINTAN NITINKUMAR SHAH AND UP TO [●] EQUITY SHARES AGGREGATING UP TO ₹ 730.00 MILLION BY SHEKHAR RASIKLAL SOMANI (COLLECTIVELY THE "PROMOTER SELLING SHAREHOLDERS") AND UP TO [●] EQUITY SHARES AGGREGATING UP TO ₹ 103.00 MILLION BY DARSHANA NITINKUMAR SHAH, UP TO [●] EQUITY SHARES AGGREGATING UP TO ₹ 342.00 MILLION BY PRITI AJAYKUMAR PATEL, UP TO [●] EQUITY SHARES AGGREGATING UP TO ₹ 342.00 MILLION BY AJAY MANSUKHLAL PATEL HUF, UP TO [●] EQUITY SHARES AGGREGATING UP TO ₹ 110.00 MILLION BY KAJAL SHEKHAR SOMANI, UP TO [●] EQUITY SHARES AGGREGATING UP TO ₹ 11.00 MILLION BY SHITALKUMAR RASIKLAL SOMANI AND UP TO [●] EQUITY SHARES AGGREGATING UP TO ₹ 65.00 MILLION BY SAMIRKUMAR RASIKLAL SOMANI (COLLECTIVELY THE "PROMOTER GROUP SELLING SHAREHOLDERS" AND TOGETHER WITH THE PROMOTER SELLING SHAREHOLDERS, THE "SELLING SHAREHOLDERS") (THE "OFFER FOR SALE" AND TOGETHER WITH THE FRESH ISSUE, THE "OFFER"). THE OFFER WILL CONSTITUTE [•]% OF OUR POST-OFFER PAID-UP EQUITY SHARE CAPITAL.

QIB Portion: Not more than 50% of the Offer

Retail Portion: Not less than 35% of the Offer

Non-Institutional Portion: Not less than 15% of the Offer

Price Band: ₹1,073 to ₹1,083 per Equity Share of face value of ₹10 each.

The Floor Price is 107.3 times the face value of the Equity Shares and the Cap Price is 108.3 times the face value of the Equity Shares. Bids can be made for a minimum of 13 Equity Shares and in multiples of 13 Equity Shares thereafter.

Smart way of Application!!!

*Applications Supported by Blocked Amount ("ASBA") is a better way of applying to issues by simply blocking the fund in the bank account, For further details, check section on ASBA below

Mandatory in public issues. No cheque will be accepted.

UNIFIED PAYMENTS INTERFACE

UPI-Now available in ASBA for Retail Individual Investors ("RIIs") applying through Syndicate Members, sub-syndicate members, Registered Brokers, RTAs and CDPs. Retail Individual Investors also have the option to submit the application directly to the ASBA Bank (SCSBs) or to use the facility of linked online trading, demat and bank account. Investors are required to ensure that the bank account used for bidding is linked to their PAN.

• ASBA has to be availed by all the investors except Anchor investors (as defined in the RHP). UPI may be availed by RIIs. • For details on the ASBA and UPI process, please refer to the details given in ASBA Form and abridged prospectus and also please *ASBA has to be availed by all the investors except Anchor investors (as defined in the RHP). UPI may be availed by RIIs.* For details on the ASBA and UPI process, please refer to the details given in ASBA Form and abridged prospectus and also please refer to the section "Offer Procedure" beginning on page 312 of the RHP. * The process is also available on the website of Association of Investment Bankers of India ("AIBI"), the Stock Exchanges and in the General Information Document. ASBA Forms can be downloaded from the websites of the Stock Exchanges and can be obtained from the list of banks that is displayed on the website of SEBI at www.sebi.gov.in. For the list of UPI Apps and Banks live on IPO, please refer to the link: www.sebi.gov.in. RIIs Bidding using the UPI Mechanism may apply through the SCSBs and mobile applications whose names appear on the website of SEBI (https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmld=40) and (https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmld=43) respectively, as updated from time to time. ICICI Bank Limited has been appointed as Sponsor Bank for the Offer related grievance investors may contact: ICICI Securities Limited - Vaibava Saboo/Anurag Byas (+91 22 2288 2460) (tatvachintan.ipo@icislescurities.com, customercare@icisles.com) or JM Financial Limited - Prachee Dhuri (+91 22 6630 3030) (tatvachintan.ipo@imfl.com, grievance.ibd@jmfl.com). For UPI related queries, investors can contact NPCI at the toll free number: 18001201740 and Mail Id: ipo.upi@npci.org.in; ICICI Bank Limited at Tel: +91 22 6681 8911/23/24 and Email: kmr.saurabh@icicibacnitan the Offer at Tel: +91 (22) 4918 6200 and Email: tatva.ipo@linkintime.co.in.

Risks to Investors

- 1. The two book running lead managers ("BRLMs") associated with the Offer have handled 33 public issues in the past three years, out of which 11 issues closed below the issue price on listing date.
- 2. Average cost of acquisition of Equity Shares held by the Selling Shareholders namely Ajaykumar Mansukhlal Patel, Chintan Nitinkumar Shah, Shekhar Rasiklal Somani, Ajay Mansukhlal Patel HUF, Priti Ajaykumar Patel, Darshana Nitinkumar Shah, Kajal Shekhar Somani, Samirkumar Rasiklal Somani and Shitalkumar Rasiklal Somani is ₹1.59, ₹3.06, ₹2.87, ₹4.00, ₹2.49, ₹1.11, ₹2.69, ₹1.65 and ₹0.91 respectively and Offer Price at upper end of the Price Band is ₹1,083 per Equity Share.
- 3. Weighted Average Return on Net Worth for Fiscals 2021, 2020, 2019 is 30.75%.

BID/OFFER PROGRAMME

OPENS ON: FRIDAY, JULY 16, 2021*

CLOSES ON: TUESDAY, JULY 20, 2021***

*Our Company may, in consultation with the BRLMs, consider participation by Anchor Investors in accordance with the SEBI ICDR Regulations. The Anchor Investor Bidding Date shall be one Working Day prior to the Bid / Offer Opening Date. ** Our Company and the Investor Selling Shareholders may, in consultation with the BRLMs, consider closing the Bid / Offer Period for QIBs one Working Day prior to the Bid / Offer Closing Date in accordance with the SEBI ICDR Regulations *UPI Mandate end time and date shall be at 12:00 pm on July 22, 2021.

In case of any revision in the Price Band, the Bid / Offer Period will be extended by at least three additional Working Days after such revision in the Price Band, subject to the Bid / Offer Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar circumstances, our Company may, for reasons to be recorded in writing, extend the Bid / Offer Period for a minimum of three Working Days, subject to the Bid / Offer Period not exceeding 10 Working Days. Any revision in the Price Band and the revised Bid / Offer Period, if applicable, shall be widely disseminated by notification to the Stock Exchanges, by issuing a press release and also by indicating the change on the respective websites by holimatorito the change on the respective websites of the BRLMs and at the terminals of the Members of the Syndicate and by intimation to Designated Intermediaries and the Sponsor Bank.

This Offer is being made in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 31 of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (the "SEBIICDR Regulations"). This Offer is being made through the Book Building Process in accordance with Regulation 6(1) of the SEBI ICDR Regulations wherein not more than 50% of the Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers ("QIBs") (the "QIB Portion"), provided that our Company in consultation with the BRLMs may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis. One-third of the Anchor Investor Portion shall be reserved for domestic Mutual Funds, subject to valid Bids being received from the domestic Mutual Funds at or above the Anchor Investor Allocation Price, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only and the remainder of the QIB Portion shall be available for allocation on a proportionate sis to all QIB Bidders (other than Anchor Investors), including Mutual Funds, subject to valid Bids being receive the Offer Price. Further, not less than 15% of the Offer shall be available for allocation on a proportionate basis to Non-Institutional Bidders and not less than 35% of the Offer shall be available for allocation for Retail Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Offer Price. All Bidders, other than Anchor Investors, are mandatorily required to participate in the Offer through the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective ASBA Account, which will be blocked by the Self Certified Syndicate Banks ("SCSBs"), or through the UPI Mechanism. Anchor Investors are not permitted to participate in the Anchor Investor Portion through the ASBAProcess. For details, see "Offer Procedure" on page 312 of the RHP.

Bidders/Applicants should ensure that DPID, PAN and the Client ID and UPID (if applicable, in case RIIs) are correctly filled in the Bid-cum-Application Form. The DPID, PAN and Client ID provided in the Bid-cum-Application Form should match with the DP ID, PAN, Client ID available in the Depository database, otherwise, the Bid-cum-Application Form is liable to be rejected. Bidders/Applicants should ensure that the beneficiary account provided in the Bid-cum-Application Form is active. Bidders/Applicants should note that on the basis of the PAN, DPID and Client ID as provided in the Bid-cum-Application Form, the Bidder/Applicant may be deemed to have authorized the Depositories to provide to the Registrar to the Offer, any requested Demographic Details of the Bidder/Applicant as available on the records of the depositories. These Demographic Details may be used, among other things, for giving Allotment Advice or unblocking of ASBA Account or for other correspondence(s) related to the Offer. Bidders/Applicants are advised to update any changes to their Demographic Details as available in the records of the Depository Participants to ensure the accuracy of records. Any delay resulting from failure to update the Demographic Details would be at the

Bidders/Applicants' sole risk CONTENTS OF THE MEMORANDUM OF ASSOCIATION OF OUR COMPANY AS REGARDS ITS OBJECTS: For

171 of the RHP and Clause III of the Memorandum of Association of our Company. The Memorandum of Association of our Company is a material document for inspection in relation to the Offer. For further details, see "Material Contracts and Documents for Inspection" on page 354 of the RHP.

LIABILITY OF THE MEMBERS OF OUR COMPANY: Limited by shares.

AMOUNT OF SHARE CAPITAL OF OUR COMPANY AND CAPITAL STRUCTURE: As on the date of the RHP, the authorised

share capital of our Company is ₹400,000,000 divided into 40,000,000 Equity Shares of ₹10 each. The issued, subscribed and paid-up Equity share capital of our Company is ₹ 200, 875, 000 divided into 20,087,500 Equity Shares of ₹10 each. For details, see "Capital Structure" on page 72 of the RHP.

NAMES OF SIGNATORIES TO THE MEMORANDUM OF ASSOCIATION OF OUR COMPANY AND THE NUMBER OF EQUITY SHARES SUBSCRIBED BY THEM: 10 Equity Shares each were allotted to Ajaykumar Mansukhlal Patel, Chintan Nitinkumar Shah and Shekhar Rasiklal Somani. LISTING: The Equity Shares offered through the Red Herring Prospectus are proposed to be listed on the Stock Exchanges

Our Company has received 'in-principle' approvals from the BSE and the NSE for the listing of the Equity Shares pursuant to letters dated May 14, 2021 and May 26, 2021, respectively. For the purposes of the Offer, the Designated Stock Exchange shall be BSE. A signed copy of the Red Herring Prospectus and the Prospectus shall be filed with the RoC in accordance with Section 26(4) and 32 of the Companies Act, 2013. For details of the material contracts and documents available for inspection from the page 354 of the RHP.

DISCLAIMER CLAUSE OF THE SEBI: SEBI only gives its observations on the draft offer document and this does not constitute approval of either the issue or the specified securities stated in the offer document. The investors are advised to refer to page 290 of the RHP for the full text of the Disclaimer Clause of SEBI.

DISCLAIMER CLAUSE OF BSE (DESIGNATED STOCK EXCHANGE): It is to be distinctly understood that the permission given by BSE Limited should not in any way be deemed or construed that the Red Herring Prospectus has been cleared or approved by BSE Limited nor does it certify the correctness or completeness of any of the contents of the Red Herring Prospectus. The investors are advised to refer to page 292 of the Red Herring Prospectus for the full text of the Disclaimer Clause of The BSE Limited.

DISCLAIMER CLAUSE OF NSE: It is to be distinctly understood that the permission given by NSE should not in any way be deemed or construed that the Red Herring Prospectus has been cleared or approved by NSE nor does it certify the correctness or completeness of any of the contents of the Red Herring Prospectus. The investors are advised to refer to page 293 of the Red Herring Prospectus for the full text of the Disclaimer Clause of NSE.

GENERAL RISKS: Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in the Offer unless they can afford to take the risk of losing their investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Offer. For taking an investment decision, investors must rely on their own examination of our Company and the Offer, including the risks involved. The Equity Shares in the Offer have not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), nor does SEBI guarantee the accuracy or adequacy of the contents of the Red Herring Prospectus. Specific attention of the investors is invited to "Risk Factors" on page

CORRIGENDUM - NOTICE TO INVESTORS

This corrigendum ("Corrigendum") is with reference to the RHP filed in relation to the Offer. In this regard, please note that paragraph 17 of the section "Material Contracts and Documents for Inspection-Material documents" on page 355 of the RHP should be read as follows: "Consent of the Directors, BRLMs, Syndicate Member, the legal counsel to the Company, the legal counsel to the Book Running Lead Managers, Registrar to the Offer, Banker (s) to the Offer, Banker to our Company, Company Secretary and Compliance Officer, Chief Financial Officer and our customers, as referred to in their specific capacities. The RHP shall be read in conjunction with this Corrigendum. The RHP stands amended to the extent above. The relevant changes shall be reflected in the Prospectus when filed with the RoC, SEBI and the Stock Exchanges

BOOK RUNNING LEAD MANAGERS *I***ICICI** Securities

Investor grievance e-mail: customercare@icicisecurities.com

ICICI Securities Limited

Place: Ankleshwar

Date: July 12, 2021

ICICI Centre, H.T. Parekh Marg, Churchgate,

E-mail: tatvachintan.ipo@icicisecurities.com

Contact person: Vaibhav Saboo / Anurag Byas

Mumbai - 400 020, Maharashtra, India

Telephone: +91 22 2288 2460

Website: www.icicisecurities.com

JM FINANCIAL

7th Floor, Cnergy, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, Maharashtra, India

Investor grievance e-mail: grievance.ibd@jmfl.com

JM Financial Limited

Website: www.jmfl.com

Telephone: + 91 22 6630 3030

Contact person: Prachee Dhuri

E-mail: tatvachintan.ipo@imfl.com

REGISTRAR TO THE OFFER LINKIntime

C-101, 1st Floor, 247 Park, Lal Bahadur Shastri Marg.

Vikhroli (West), Mumbai - 400 083, Maharashtra, India

Investor grievance e-mail: tatva.ipo@linkintime.co.in

Link Intime India Private Limited

Telephone: +91 (22) 4918 6200

E-mail: tatva.ipo@linkintime.co.in

Contact person: Shanti Gopalkrishnan

Website: www.linkintime.co.in

Apurva Dubey Plot No. 353, Makarpura GIDC, Vadodara, Gujarat – 390 010, India Telephone: +91 75748 48533 / +91 75748 48534

E-mail: cs@tatvachintan.com

Website: www.tatvachintan.com

Investors can contact the Company Secretary and Compliance Officer, the BRLMs or the Registrar to the Offer in case of any pre-Offer or post-Offer related problems such as non-receipt of letters of Allotment, noncredit of Allotted Equity Shares in the respective beneficiary account, non-receipt of refund orders or nonreceipt of funds by electronic mode, etc.

COMPANY SECRETARY AND COMPLIANCE OFFICER

SEBI registration number: INM000011179 SEBI registration number: INM000010361 SEBI registration number: INR000004058 AVAILABILITY OF RHP: Investors are advised to refer to the RHP and the "Risk Factors" beginning on page 24 of the RHP, contained therein before applying in the Offer. Full copy of the RHP is available on website of SEBI at www.sebi.gov.in, websites of the BRL Ms, i.e. ICICI Securities Limited and JM Financial Limited at www.icicisecurities.com and www.jmfl.com, respectively and websites of BSE and NSE i.e. www.bseindia.com, respectively.

AVAILABILITY OF BID CUM APPLICATION FORMS: Bid cum Application Forms can be obtained from the Registered Office of the Company, Telephone: +91 75730 46951 / +91 75730 46952; Book Running Lead Managers: ICICI Securities Limited, Telephone: +91 22 2288 2460; JM Financial Limited, Telephone: +91 22 6136 3400 and at the select locations of the Sub-syndicate Members, SCSBs, Registered Brokers, RTAs and CDPs participating in the Offer. ASBA Forms will also be available on the websites of BSE and NSE at www.bseindia.com and twww.nseindia.com and the Designated Branches of SCSBs, the list of which is available at websites of the Stock Exphanges and SEBI.

Exchanges and SEBI.

Sub-Syndicate Members: Almondz Global Securities Ltd, Anand Rathi Share & Stock Brokers Ltd, Axis Capital Ltd, Bajaj Financial Securities Ltd, Centrum Broking Ltd, Choice Equity Broking Private Limited, DB(International) Stock Brokers Ltd, Edelweiss Broking Ltd, Eureka Stock & Share Broking Services Ltd, Globe Capital Market Ltd, ICICI Securities Ltd, IVP Securities Ltd, Jobanputra Fiscal Services Pvt. Ltd, KJMC Capital Market Dervices Ltd, Kotak Securities Ltd, LKP Securities Ltd, Motilal Oswal Financial Services Limited, Motilal Oswal Financial Services Ltd, SBICAP Securities Ltd, SMC Global Securities Ltd, Systematix Shares and Stocks (India) Limited, Trade Bulls Securities Ltd

Escrow Collection Bank, Refund Bank, Public Offer Account Bank and Sponsor Bank: ICICI Bank Limited

UPI: Retail Individual Investors can also Bid through UPI mechanism.

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the RHP.

For TATVA CHINTAN PHARMA CHEM LIMITED

On behalf of the Board of Directors

Company Secretary and Compliance Officer

TATVA CHINTAN PHARMA CHEM LIMITED is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offering of its Equity Shares and has filed the RHP with the RoC and thereafter with SEBI and the Stock Exchanges i.e. BSE and NSE at www.bseiindia.com and www.nseindia.com, respectively and is available on the websites of the BRLMs i.e. ICICI Securities Limited and JM Financial Limited at www.icicisecurities.com and www.irinfl.com, respectively. Bidders should note that investment in equity shares involves a high degree of risk and for details relating to the same, please see the section entitled "Risk Factors" on page 24 of the RHP. Potential Bidders should not rely on the DRHP filed with SEBI for making any investment decision.

The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or any state securities laws in the United States and, unless so registered, may not be offered or sold within the United States,

except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. Accordingly, the Equity Shares are only being offered and sold outside the United States in offshore transactions in reliance on Regulation S under the Securities Act and the applicable laws of the jurisdictions where those offers and sales are made. There will be no public offering in the United States.